Bank of America (BofA) Securities has maintained a ‘Neutral’ rating on Zydus Life, with a target price of ₹1,040, indicating potential upside from the current market price of ₹901.50 (as of March 11). The brokerage believes that Zydus Life’s €390 million acquisition of Amplitude Surgical could strengthen its presence in the knee and hip replacement segment, offering growth opportunities in the medtech sector.
According to BofA Securities, the acquisition provides scope for market share expansion in existing regions and supports geographic growth. Additionally, the company’s entry into medtech aligns with its broader strategy, with a particular focus on cardiology, orthopedics, and nephrology.
On Monday, Zydus Life’s stock gained 0.87% to ₹901.50, reflecting steady investor sentiment despite mixed analyst views. While UBS remains cautious, citing high acquisition costs and low RoCE, BofA Securities sees growth potential in new therapeutic segments.
Disclaimer: The above stock recommendations are based on brokerage reports and do not constitute financial advice. Investors are advised to conduct their own research before making investment decisions.
